Revvity Receives FDA Clearance for Total Testosterone Assay Enabling Comprehensive Automated Testosterone Testing Solution

Key Takeaways

• Total testosterone assay now FDA‑cleared on IDS platform
• Single‑platform testing replaces complex ED‑LC/MS workflows
• Portfolio now covers total, free testosterone and SHBG
• Supports first‑ and second‑line hypogonadism diagnosis

Pulse Analysis

The clinical assessment of testosterone levels has long been hampered by fragmented testing methods. Traditional approaches often require separate assays for total and free testosterone, plus a separate measurement of sex hormone‑binding globulin (SHBG). Laboratories then resort to equilibrium‑dialysis liquid chromatography/mass spectrometry (ED‑LC/MS) to reconcile these values, a process that is labor‑intensive, costly, and prone to variability. Revvity’s chemiluminescence immunoassay (ChLIA) platform consolidates these measurements, delivering high‑throughput, automated results that meet the precision standards demanded by endocrinologists.

The recent FDA clearance of Revvity’s Total Testosterone assay completes the company’s ChLIA trio, allowing clinicians to order a comprehensive testosterone panel from a single instrument. This integration streamlines workflow, reduces turnaround time, and eliminates the need for specialized LC/MS equipment, which many midsize labs lack. By offering first‑ and second‑line diagnostic capability, the suite can serve both initial screening and confirmatory testing, enhancing diagnostic confidence for hypogonadism and other androgen‑related disorders in men and women.

Beyond immediate laboratory efficiencies, the clearance signals a strategic shift in the endocrine diagnostics market. Revvity, a S&P 500 company with $2.9 billion in projected 2025 revenue, is positioning itself as a one‑stop provider of automated hormone assays. Competitors will need to match this breadth of FDA‑cleared offerings or risk losing market share. As personalized medicine expands, integrated platforms that combine speed, accuracy, and cost‑effectiveness will become essential, and Revvity’s move may set a new benchmark for future assay development.